Cardiovascular disease (CVD) is one of the most common diseases worldwide. The underlying pathogenesis of the disease has not yet been determined, but many factors have been identified. Tet methylcytosine dioxygenase 2 (TET2) is one of the epigenetic factors involved in regulating many genes. Therefore, based on the studies shown, this factor plays an important role in preventing the occurrence of CVD. TET2 has been shown to increase angiogenesis by expressing Robo4. It also increases the activity of Matrix metalloproteinases (MMPs) and stimulates the secretion of Vascular endothelial growth factor angiogenesis. On the other hand, it has been shown that TET2 regulates the expression of several genes and the development of the heart during the embryonic period due to its oxygenating role. TET2 has been shown to regulates the expression of the genes such as Ying Yang1 (YY1), Sox9b, Inhbaa and many other genes that ultimately lead to the differentiation of cardiomyocytes. On the other hand, it has been shown that some Long non coding RNA and MicroRNAs reduce TET2 expression and CVD. Finally, it is concluded that inducing TET2 expression can be a good therapeutic strategy to prevent or improve CVD.

Ovarian cancer (OC) remains a leading cause of gynecologic cancer mortality due to its biological heterogeneity, late-stage diagnosis, and resistance to conventional therapies. The tumor microenvironment (TME) plays a critical role in driving disease progression, with pathological interactions between activated platelets and leukocytes significantly contributing to immune evasion, metastasis, and thromboinflammation. Platelet-derived P-selectin facilitates platelet–neutrophil aggregation, leading to the formation of neutrophil extracellular traps (NETs) via NETosis, which further promotes tumor growth and thrombotic complications. In addition, platelet-secreted TGF-β1 enhances an immunosuppressive environment, inducing epithelial-to-mesenchymal transition (EMT) and skewing immune cell polarization toward tumor-promoting phenotypes. In this review, we explore the mechanistic role of platelet–leukocyte interactions in OC progression and examine current pharmacologic challenges in targeting these interactions. We then propose a novel therapeutic strategy involving pH-responsive nanoparticles co-loaded with anti-platelet agents and doxorubicin, designed to selectively release their payload within the acidic TME. This nanodrug aims to inhibit platelet activation, reduce NET formation, and enhance local cytotoxic efficacy while minimizing systemic toxicity and bleeding risk—common challenges with conventional therapies. By integrating principles from tumor immunology, hemostasis, and nanomedicine, our strategy offers a promising, multi-targeted approach to OC therapy. We advocate for further preclinical and clinical studies to assess the potential of this nanodrug in overcoming immune resistance and thromboinflammatory complications in advanced ovarian cancer.